Viola Caretti
YOU?
Author Swipe
View article: A narrative review on treatment strategies for neonatal hypoxic ischemic encephalopathy
A narrative review on treatment strategies for neonatal hypoxic ischemic encephalopathy Open
TH successfully improves outcomes after HIE, and it continues to be optimized. Larger studies are needed to understand its use in mild cases of HIE and if certain factors, such as sex, affect long term outcomes. TH primarily acts in the in…
View article: Data from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models
Data from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models Open
The role of the VEGF inhibitor bevacizumab in the treatment of diffuse intrinsic pontine glioma (DIPG) is unclear. We aim to study the biodistribution and uptake of zirconium-89 (89Zr)-labeled bevacizumab in DIPG mouse models. Human E98-FM…
View article: Supplementary figure legends from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models
Supplementary figure legends from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models Open
Supplementary figure legends, supplementary figure 1 and 2
View article: Data from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models
Data from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models Open
The role of the VEGF inhibitor bevacizumab in the treatment of diffuse intrinsic pontine glioma (DIPG) is unclear. We aim to study the biodistribution and uptake of zirconium-89 (89Zr)-labeled bevacizumab in DIPG mouse models. Human E98-FM…
View article: Supplemental figure 2 from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models
Supplemental figure 2 from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models Open
Supplemental Figure 2: VEGF mRNA expression in DIPG in comparison to normal brain (n=31) as analyzed by R2 (R2.amc.nl), clustered by stage of disease; unknown (n=10), pretreatment (n=2) and postmortem (n=23)
View article: Supplemental figure 1 from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models
Supplemental figure 1 from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models Open
A heatmap generated using K-means clustering of expression of VEGF-A associated genes; LG-BSG samples (blue) in the disease type histology (upper legends) cluster with normal brain (purple). DIPG (red) clusters with GBM (green). DIPG (gree…
View article: Supplementary figure legends from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models
Supplementary figure legends from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models Open
Supplementary figure legends, supplementary figure 1 and 2
View article: Supplemental figure 1 from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models
Supplemental figure 1 from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models Open
A heatmap generated using K-means clustering of expression of VEGF-A associated genes; LG-BSG samples (blue) in the disease type histology (upper legends) cluster with normal brain (purple). DIPG (red) clusters with GBM (green). DIPG (gree…
View article: Supplemental figure 2 from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models
Supplemental figure 2 from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of <sup>89</sup>Zr-Bevacizumab PET Imaging in Brain Tumor Models Open
Supplemental Figure 2: VEGF mRNA expression in DIPG in comparison to normal brain (n=31) as analyzed by R2 (R2.amc.nl), clustered by stage of disease; unknown (n=10), pretreatment (n=2) and postmortem (n=23)
View article: Supplementary Figure 5 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 5 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 40K, HGF expression.
View article: Supplementary Figure 6 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 6 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 283K, Modulation of CDA activity and ROS levels.
View article: Data from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Data from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
Pancreatic ductal adenocarcinoma (PDAC) remains a major unsolved health problem. Most drugs that pass preclinical tests fail in these patients, emphasizing the need of improved preclinical models to test novel anticancer strategies. Here, …
View article: Supplementary Video 1 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Video 1 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
GIF file - 2361K, High-frequency ultrasound.
View article: Supplementary Figure 4 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 4 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 1445K, Genetic characterization of the PDAC-FM-GC mouse models.
View article: Supplementary Figure 2 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 2 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 276K, Comparative IHC staining in human samples and orthotopic tumor grafts.
View article: Supplementary Figure Legend from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure Legend from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 129K
View article: Supplementary Figure 6 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 6 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 283K, Modulation of CDA activity and ROS levels.
View article: Supplementary Figure 2 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 2 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 276K, Comparative IHC staining in human samples and orthotopic tumor grafts.
View article: Data from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Data from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
Pancreatic ductal adenocarcinoma (PDAC) remains a major unsolved health problem. Most drugs that pass preclinical tests fail in these patients, emphasizing the need of improved preclinical models to test novel anticancer strategies. Here, …
View article: Supplementary Figure 5 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 5 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 40K, HGF expression.
View article: Supplementary Methods from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Methods from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 155K, Description of additional methods and procedures used in the study. Also includes supplemental references.
View article: Supplementary Figure 4 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 4 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 1445K, Genetic characterization of the PDAC-FM-GC mouse models.
View article: Supplementary Methods from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Methods from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 155K, Description of additional methods and procedures used in the study. Also includes supplemental references.
View article: Supplementary Figure 1 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 1 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 353K, BLI quantification of tumor growth and survival analysis in PDAC-1/2/3/4-FM-GC mouse models.
View article: Supplementary Figure 3 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 3 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 189K, H&E and IHC staining demonstrating the human origin of the PDAC-FM-GC mouse models.
View article: Supplementary Figure 8 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 8 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 42K, Concentrations of crizotinib and gemcitabine in blood samples.
View article: Supplementary Figure Legend from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure Legend from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 129K
View article: Supplementary Figure 8 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 8 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 42K, Concentrations of crizotinib and gemcitabine in blood samples.
View article: Supplementary Figure 7 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
Supplementary Figure 7 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Open
PDF file - 55K, Correlation between BLI data and volumes detected at high frequency ultrasound.